High Risk Myelodysplastic Syndrome Clinical Trials

38 clinical trials for High Risk Myelodysplastic Syndrome across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• RVU120 Rollover Study — RECRUITING · PHASE2
• Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — RECRUITING · PHASE1
• Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital — RECRUITING
• Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers — RECRUITING · PHASE2
• Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — RECRUITING · PHASE2
• A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias — RECRUITING · PHASE1
• Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy — RECRUITING · PHASE1
• Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies — RECRUITING · PHASE1
• The Patient Cohort of the National Center for Precision Medicine in Leukemia — RECRUITING
• GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors — NOT_YET_RECRUITING · PHASE1
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE2
• Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome — COMPLETED · PHASE2
• Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML — NOT_YET_RECRUITING · PHASE1
• Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN — NOT_YET_RECRUITING · PHASE2
• Hu8F4 in Treating Patients With Advanced Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome — ACTIVE_NOT_RECRUITING · PHASE1
• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS — NOT_YET_RECRUITING · PHASE1
• A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT — ACTIVE_NOT_RECRUITING · PHASE2
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia — COMPLETED · PHASE1
• Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) — TERMINATED · PHASE1
• Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes — COMPLETED · PHASE2
• Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML — ACTIVE_NOT_RECRUITING · PHASE2
• Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome — COMPLETED · PHASE1
• RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome — OTHER · PHASE1
• A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS — OTHER · PHASE1
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies — COMPLETED · PHASE1
• Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — TERMINATED · PHASE2
• Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome — OTHER · PHASE2
• A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome — COMPLETED · PHASE1
• Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes — COMPLETED · PHASE2
• Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies — COMPLETED · PHASE1
• Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — COMPLETED · PHASE1
• Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome — TERMINATED · PHASE1
• Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) — TERMINATED · PHASE2
• Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias — COMPLETED · PHASE1
• A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. — COMPLETED · PHASE1

Refine this search